Molbio Diagnostics
Molbio Diagnostics
HealthcareKey Fundamentals
SmallcapTapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
3- Company is almost debt free.
- Debtor days have improved from 108 to 63.3 days.
- Company's working capital requirements have reduced from 169 days to 114 days
Growth Rate
AI Analysis — Bull vs Bear
anthropic claude-opus-4.6 3d agoMolbio Diagnostics trades at a market cap of ₹16,073 Cr with a PE of 88.3x and PB of 10.59x, reflecting premium valuations. The company is almost debt free with improving working capital efficiency (debtor days down to 63.3 from 108), but profitability growth has been inconsistent with 5-year compounded profit CAGR at -19% despite a TTM sales growth of 35%.
- Company is almost debt free, providing financial flexibility and low interest burden in a high-rate environment
- TTM compounded sales growth stands at 35%, indicating strong recent revenue momentum
- 3-year compounded sales CAGR of 59% reflects an exceptional medium-term revenue expansion track record
- 3-year compounded profit CAGR of 111% shows the company has delivered outsized earnings growth over the medium term
- Debtor days improved significantly from 108 to 63.3 days, signaling better receivables management and faster cash conversion
- Working capital cycle reduced from 169 days to 114 days, freeing up capital for reinvestment and improving cash flow quality
- ROE has remained steady at 15-16% over the last 3 and 5 years, indicating consistent return generation on shareholder equity
- Operating in the diagnostics and healthcare sector which benefits from structural tailwinds including rising health awareness and expanding testing infrastructure in India
- PE ratio of 88.3x is significantly elevated compared to broader market and most healthcare peers, leaving limited margin of safety
- 5-year compounded profit CAGR is -19%, indicating that longer-term earnings trajectory has actually declined, likely due to post-COVID normalization
- TTM compounded profit growth is only 1%, suggesting current earnings momentum has stalled despite 35% sales growth — pointing to margin compression
- PB ratio of 10.59x implies the stock is priced at a steep premium to book value, which increases downside risk if growth disappoints
- Zero dividend yield means shareholders rely entirely on capital appreciation with no income cushion during drawdowns
- 5-year compounded sales CAGR of just 1% raises questions about underlying organic growth once the COVID-era testing surge is stripped out
- ROE of 15% in the last year, while decent, does not justify a PB of 10.59x — the implied cost of equity required to sustain this valuation is very high
- 52-week high and low data are unavailable (reported as 0), limiting visibility into recent price range and volatility context
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
anthropic claude-opus-4.6 5h ago- Geographic & forex concerns Sep 7
Management flagged geographic mix, foreign exchange fluctuations, and the OptraScan business as areas of concern for upcoming growth.
- Low capacity utilization Sep 12
Device capacity utilization stands at just 42% and test-kit utilization at 58% in FY26, indicating significant idle capacity that needs to be filled.
- Non-linear quarterly business Sep 7
Management cautioned that the business is not quarterly linear due to public health procurement dynamics, making quarter-to-quarter comparisons unreliable.
- Deferred revenue inflated Q1 Sep 12
Q1FY27 profit surge of 523% was partly driven by ₹57 crore in deferred export revenue recognition, not purely organic demand growth.
- Q1FY27 profit surges 523% Sep 12
Consolidated net profit surged 523% YoY to ₹52.7 crore in Q1FY27, with revenue rising fourfold to ₹411.5 crore and sales up 309.57%.
- Stock surges 109% from IPO Sep 7
Molbio hit a record high of ₹1,686.50 on Sep 11, surging 109% from its ₹807 IPO price, with market cap reaching ₹17,394 crore.
- Truenat kit volumes 8x jump Sep 7
Truenat test-kit volumes rose sharply to 62.4 lakh units in Q1FY27 from 7.9 lakh units YoY, across 12,500+ devices in 90+ countries.
- Strong FY27 growth guidance Sep 7
Management guided for ~25% topline growth and 24-25% EBITDA margins for FY27, backed by 60-63% gross margins and a $30 billion POC market growing at 17.9% CAGR.
- US FDA clearance for OptraScan Sep 12
OptraScan received US FDA clearance for digital pathology solutions, with meaningful revenue contribution expected from FY28.
- IPO proceeds fueling R&D capex Sep 7
Molbio deploying ₹105.5 crore towards R&D facility via subsidiary Bigtec and ₹72.2 crore for plant and machinery at Goa and Visakhapatnam facilities.
- FY26 profitability turnaround Sep 7
FY26 net profit rose 14.8% YoY to ₹166.6 crore, revenue grew 41.7% to ₹1,445.7 crore, and EBITDA turned positive at ₹101 crore with 24.6% margins.
- Q1FY27 earnings call scheduled Sep 2
Molbio Diagnostics scheduled its Q1FY27 earnings conference call for September 8, 2026 at 4:00 pm IST.
- Prognosys subsidiary contribution Sep 12
Prognosys contributed ₹11 crore to Q1 revenue, with full-year EBITDA margins expected near 19%.
TL;DR: Molbio Diagnostics is executing well post-IPO with explosive Q1FY27 growth — profit up 523%, revenue up 4x, and Truenat kit volumes jumping 8x. The stock has doubled from its IPO price, supported by strong FY27 guidance of 25% topline growth and 24-25% EBITDA margins. Key risks include reliance on deferred revenue recognition, forex exposure, and non-linear quarterly procurement patterns. With significant capacity headroom and IPO proceeds being deployed into R&D and manufacturing, the growth trajectory looks favorable if test-kit adoption continues scaling globally.
Quarterly Results
| Particulars | Jun 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|
| Sales | 95 | 439 | 399 |
| Expenses | 105 | 332 | 308 |
| Operating Profit | -10 | 107 | 92 |
| OPM % | -10% | 24% | 23% |
| Other Income | 1 | 3 | 1 |
| Interest | 2 | 9 | 9 |
| Depreciation | 7 | 10 | 8 |
| PBT | -17 | 91 | 76 |
| Tax % | -23% | 28% | 25% |
| Net Profit | -13 | 66 | 57 |
| EPS in Rs | -5.95 | 5.83 | 5.02 |
Profit & Loss
| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Sales | 1,271 | 776 | 327 | 756 | 971 | 1,313 |
| Expenses | 676 | 457 | 286 | 552 | 746 | 1,062 |
| Operating Profit | 595 | 319 | 40 | 204 | 226 | 252 |
| OPM % | 47% | 41% | 12% | 27% | 23% | 19% |
| Other Income | 1 | 5 | 8 | -21 | -2 | 5 |
| Interest | 35 | 25 | 6 | 8 | 9 | 23 |
| Depreciation | 12 | 42 | 19 | 24 | 26 | 36 |
| PBT | 549 | 258 | 23 | 152 | 188 | 198 |
| Tax % | 25% | 27% | 32% | 27% | 26% | 27% |
| Net Profit | 410 | 187 | 16 | 111 | 140 | 145 |
| EPS in Rs | 2,027 | 833 | 69 | 493 | 62 | 12.83 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
Balance Sheet
| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity Capital | 2 | 2 | 2 | 2 | 2 | — |
| Reserves | 333 | 681 | 737 | 848 | 988 | — |
| Borrowings | 257 | 105 | 57 | 70 | 26 | — |
| Other Liabilities | 215 | 85 | 123 | 157 | 291 | — |
| Total Liabilities | 806 | 874 | 920 | 1,077 | 1,307 | — |
| Fixed Assets | 55 | 182 | 189 | 209 | 215 | — |
| CWIP | 100 | 0 | 0 | 2 | 18 | — |
| Investments | 9 | 9 | 54 | 54 | 95 | — |
| Other Assets | 643 | 683 | 676 | 813 | 980 | — |
| Total Assets | 806 | 874 | 920 | 1,077 | 1,307 | — |
Cash Flow
| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Operating | 344 | 98 | 68 | 38 | 249 | — |
| Investing | -142 | -87 | -51 | -31 | -98 | — |
| Financing | -192 | -20 | 31 | -24 | -17 | — |
| Net Cash Flow | 10 | -9 | 48 | -18 | 133 | — |
| Free Cash Flow | 212 | 35 | 55 | 24 | 206 | — |
| CFO/OP | 78 | 53 | 251 | 39 | 139 | — |
Ratios
| Particulars | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Debtor Days | 61 | 113 | 194 | 174 | 86 | — |
| Inventory Days | 261 | 402 | 885 | 393 | 395 | — |
| Days Payable | 124 | 64 | 201 | 129 | 226 | — |
| Cash Conversion Cycle | 198 | 450 | 877 | 438 | 254 | — |
| Working Capital Days | 75 | 206 | 479 | 239 | 155 | — |
| ROCE % | — | 41% | 4% | 22% | 21% | — |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Molbio Diagnostics insights
0 extracted metrics + investor summaries across FY–FY.
Documents
Frequently Asked Questions about Molbio Diagnostics
What does Molbio Diagnostics Ltd do?
Where is Molbio Diagnostics Ltd (1286089) listed?
Which sector does Molbio Diagnostics Ltd belong to?
What is the market capitalisation of Molbio Diagnostics Ltd?
What is the PE ratio of Molbio Diagnostics Ltd?
What is the 52-week high and low of Molbio Diagnostics Ltd?
What is the Return on Equity (ROE) of Molbio Diagnostics Ltd?
Company Information
Molbio Diagnostics is an innovative point- of-care (POC) diagnostics company that develops affordable, rapid, and accurate diagnostic solutions for infectious and non-communicable diseases. Its flagship product, Truenat, is a portable, battery-powered PCR testing platform that delivers results within an hour. Designed for use in resource-limited settings, it enables quick and decentralised disease diagnosis at the point of care. Through its wholly owned subsidiary, Bigtec Labs, Molbio has strong research and development capabilities focused on creating diagnostic platforms for point-of- care (POC) testing. From product development to large-scale deployment, the company aims to improve access to reliable and affordable healthcare for everyone. https://www.molbiodiagnostics.com/wp-content/uploads/2026/08/Molbio-Diagnostics-Limited-Red-Herring-Prospectus.pdf#page=215 #}
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/1286089.md for Molbio Diagnostics Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.